GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Cyclically Adjusted Price-to-FCF

Synergy Pharmaceuticals (FRA:S90) Cyclically Adjusted Price-to-FCF : (As of May. 17, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Synergy Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Synergy Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Synergy Pharmaceuticals Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Synergy Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Synergy Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2018 is calculated as:

For example, Synergy Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2018 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2018 (Change)*Current CPI (Sep. 2018)
=-0.054/106.5067*106.5067
=-0.054

Current CPI (Sep. 2018) = 106.5067.

Synergy Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200812 -0.016 88.697 -0.019
200903 -0.005 89.744 -0.006
200906 -0.013 91.003 -0.015
200909 -0.022 91.120 -0.026
200912 -0.037 91.111 -0.043
201003 -0.025 91.821 -0.029
201006 -0.024 91.962 -0.028
201009 -0.027 92.162 -0.031
201012 -0.042 92.474 -0.048
201103 -0.046 94.283 -0.052
201106 -0.059 95.235 -0.066
201109 -0.042 95.727 -0.047
201112 -0.175 95.213 -0.196
201203 -0.095 96.783 -0.105
201206 -0.092 96.819 -0.101
201209 -0.109 97.633 -0.119
201212 -0.093 96.871 -0.102
201303 -0.167 98.209 -0.181
201306 -0.116 98.518 -0.125
201309 -0.085 98.790 -0.092
201312 -0.113 98.326 -0.122
201403 -0.157 99.695 -0.168
201406 -0.153 100.560 -0.162
201409 -0.173 100.428 -0.183
201412 -0.240 99.070 -0.258
201503 -0.221 99.621 -0.236
201506 -0.230 100.684 -0.243
201509 -0.174 100.392 -0.185
201512 -0.245 99.792 -0.261
201603 -0.211 100.470 -0.224
201606 -0.174 101.688 -0.182
201609 -0.158 101.861 -0.165
201612 -0.187 101.863 -0.196
201703 -0.275 102.862 -0.285
201706 -0.227 103.349 -0.234
201709 -0.221 104.136 -0.226
201712 -0.118 104.011 -0.121
201803 -0.118 105.290 -0.119
201806 -0.131 106.317 -0.131
201809 -0.054 106.507 -0.054

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Synergy Pharmaceuticals  (FRA:S90) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Synergy Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines